RO 316840

Drug Profile

RO 316840

Alternative Names: 2' BFddC; F DDC; Fluoro DDC; Fluoro-DDCYD

Latest Information Update: 14 Nov 2006

Price : $50

At a glance

  • Originator Roche
  • Class Antiretrovirals; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B; HIV infections

Most Recent Events

  • 29 Oct 1999 No-Development-Reported for Hepatitis B in USA (Unknown route)
  • 29 Oct 1999 No-Development-Reported for HIV infections treatment in United Kingdom (Unknown route)
  • 17 Nov 1994 Preclinical development for Hepatitis B in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top